Transitioned from a clinical-stage entity to a commercially minded organization through a strategic restructuring and leadership strengthening in late 2025. Performance in 2025 was driven by Rytelo's first full year of commercial availability, establishing a footprint of approximately 1,300 prescribing accounts. Strategic focus has shifted squarely to the second-line lower-risk MDS setting, where management believes Rytelo offers the most significant clinical impact and market opportunity. Market dy ...